| NCT06656416 | ALTO-100 in Bipolar Disorder With Depression (BD-D) | RECRUITING | PHASE2 | 2024-10-02 | 2026-10 | 2026-08 |
| NCT06502964 | Study of ALTO-101 in Patients With Schizophrenia | RECRUITING | PHASE2 | 2024-06-11 | 2025-11 | 2025-10 |
| NCT06391593 | PD, PK, and Safety of ALTO-203 in Patients With MDD | RECRUITING | PHASE2 | 2024-03-25 | 2025-05 | 2025-04 |
| NCT05922878 | Study of ALTO-300 in MDD | RECRUITING | PHASE2 | 2023-06-08 | 2026-12 | 2026-12 |
| NCT05712187 | Phase 2b Study of ALTO-100 in MDD | COMPLETED | PHASE2 | 2023-01-10 | 2024-10-24 | 2024-09-05 |
| NCT05419869 | Pilot Decentralized Trial | COMPLETED | PHASE2 | 2022-06-01 | 2023-01-26 | 2023-01-13 |
| NCT05157945 | ALTO-300 in Depression (ALTO-300-004) | COMPLETED | PHASE2 | 2022-02-03 | 2023-05-05 | 2023-04-26 |
| NCT05117632 | ALTO-100 in MDD and/or PTSD | COMPLETED | PHASE2 | 2021-12-20 | 2022-12-09 | 2022-12-01 |
| NCT05118750 | ALTO-300 in Depression | COMPLETED | PHASE2 | 2021-12-13 | 2023-05-09 | 2023-05-05 |
| NCT04388202 | Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram | WITHDRAWN | PHASE4 | 2020-10-15 | 2023-05-30 | 2023-05-30 |
| NCT04388189 | Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion | WITHDRAWN | PHASE4 | 2020-10-15 | 2023-05-30 | 2023-05-30 |